Pharmacogenetics of Uridine Diphosphoglucuronosyltransferase (UGT) 1A Family Members and its Role in Patient Response to Irinotecan

Abstract

Glucuronidation, catalyzed by the glucuronosyltransferase (UGT) superfamily, is a major biotransformation pathway for several drugs, including irinotecan. Irinotecan is commonly used in colorectal cancer chemotherapy. Irinotecan undergoes metabolism in humans and is converted to its active metabolite SN-38, a topoisomerase I inhibitor. SN-38 is inactivated via glucuronidation catalyzed by various hepatic and extrahepatic UGT1A isozymes. Although the role of the UGT1A1 *28 genetic variant has received much attention in altered toxicity upon irinotecan treatment, other UGT1A enzymes also play an important role. This review summarizes pharmacokinetic, toxicologic, and pharmacogenetic studies carried out to date in irinotecan and SN-38 disposition.

Key Words :

• Drug-related toxicity
• Genetic polymorphisms
• Irinotecan
• Pharmacogenetics
• Uridine diphosphoglucuronosyltransferases

Notes

*Presented at the 13^th North American International Society for the Study of Xenobiotics Meeting/20^th Japanese Society for the Study of Xenobiotics Meeting, Maui, Hawaii, October 23–27, 2005.